NAV

Roquinimex

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Roquinimex
DrugBank Accession Number
DB11366
Background

Roquinimex is a derivative of quinoline that presents immunostimulant properties. Its effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and to decrease the synthesis of TNF alpha.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 308.337
Monoisotopic: 308.116092383
Chemical Formula
C18H16N2O3
Synonyms
  • Linomide
  • Roquinimex
External IDs
  • FCF 89
  • FCF-89
  • LS 2616
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Roquinimex is investigated to be used as a treatment of a number of cancers and autoimmune conditions.

As well, roquinimex is researched to be used as adjuvant therapy after bone marrow transplantation in cases of acute leukemia.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Hover over products below to view reaction partners

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
Alendronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Alendronic acid.
AmbroxolThe risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Roquinimex is combined with Benzyl alcohol.
Food Interactions
Not Available

Categories

ATC Codes
L03AX02 — Roquinimex
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Aromatic anilides
Alternative Parents
Quinoline-3-carboxamides / Hydroquinolones / Hydroxyquinolines / Hydroquinolines / Pyridinecarboxylic acids and derivatives / Hydroxypyridines / Pyridinones / Tertiary carboxylic acid amides / Vinylogous acids / Vinylogous amides
show 8 more
Substituents
Aromatic anilide / Aromatic heteropolycyclic compound / Azacycle / Carboxamide group / Carboxylic acid derivative / Dihydroquinoline / Dihydroquinolone / Heteroaromatic compound / Hydrocarbon derivative / Hydroxypyridine
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
372T2944C0
CAS number
84088-42-6
InChI Key
SGOOQMRIPALTEL-UHFFFAOYSA-N
InChI
InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3
IUPAC Name
4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
SMILES
CN(C(=O)C1=C(O)C2=C(C=CC=C2)N(C)C1=O)C1=CC=CC=C1

References

Synthesis Reference

E. Eriksoo et al., EP 59698; eidem, U.S. Patent 4,738,971 (1982, 1988 both to AB Leo).

General References
Not Available
PubChem Compound
54676478
PubChem Substance
347827974
ChemSpider
10619239
ChEBI
92056
ChEMBL
CHEMBL11672
ZINC
ZINC000100001952
Wikipedia
Roquinimex

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.123 mg/mLALOGPS
logP1.57ALOGPS
logP1.59Chemaxon
logS-3.4ALOGPS
pKa (Strongest Acidic)6.03Chemaxon
pKa (Strongest Basic)-2.4Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area60.85 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity87.75 m3·mol-1Chemaxon
Polarizability31.61 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0090000000-082e0b1391bf800ece8a
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0zfr-0098000000-da228f03b95cf2e1bac9
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0890000000-95f5de0b0faa6d413769
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0090000000-6fa2e8e9fc3b792726dd
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0zfr-0930000000-96d3ca56d461181d2bcd
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0zfr-4940000000-138425cb013568c25966
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-185.1965986
predicted
DarkChem Lite v0.1.0
[M-H]-172.60225
predicted
DeepCCS 1.0 (2019)
[M+H]+184.6132986
predicted
DarkChem Lite v0.1.0
[M+H]+174.96024
predicted
DeepCCS 1.0 (2019)
[M+Na]+185.0801986
predicted
DarkChem Lite v0.1.0
[M+Na]+181.90071
predicted
DeepCCS 1.0 (2019)

Drug created at February 10, 2016 22:31 / Updated at February 21, 2021 18:53